Clinical Trial Update: A Phase 3 Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria (CSU) [Phase 3]

View source ↗

Summary

This update notes that a Phase 3 trial of Barzolvolimab for chronic spontaneous urticaria is active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Spontaneous Urticaria

Drugs mentioned

• Barzolvolimab (barzolvolimab)

Snippet

Sponsor: Celldex Therapeutics | Conditions: Chronic Spontaneous Urticaria | Phase 3 | Status: ACTIVE_NOT_RECRUITING